Pitavastatin in the Prevention of Cardiovascular Disease in People Living with HIV: A Review

Area of Science:

• Cardiology
• Infectious Diseases
• Pharmacology

Background:

• Human Immunodeficiency Virus (HIV) infection is linked to increased cardiovascular disease (CVD) risk.
• Mechanisms include inflammation, atherogenesis, and drug interactions with antiretroviral therapy (ART).
• HIV is an independent risk factor for CVD development.

Purpose of the Study:

• To review the pathophysiologic mechanisms linking HIV to CVD.
• To evaluate the "Randomized Trial to Prevent Vascular Events in HIV" (REDUCE-IT) trial findings on pitavastatin.
• To discuss future implications of pitavastatin for managing CVD in people with HIV.

Main Methods:

• Literature review of HIV-associated CVD mechanisms.
• Analysis of the "Randomized Trial to Prevent Vascular Events in HIV" (REDUCE-IT) study.
• Synthesis of current evidence and future research directions.

Main Results:

• HIV contributes to CVD through inflammation, atherogenesis, and ART interactions.
• The REDUCE-IT trial demonstrated a significant reduction in cardiac events with pitavastatin use in people with HIV.
• Pitavastatin shows promise in mitigating cardiovascular risks in this population.

Conclusions:

• HIV significantly increases CVD risk through multiple pathways.
• Pitavastatin is a potential therapeutic agent for reducing cardiac events in people living with HIV.
• Further research is warranted to optimize pitavastatin use in HIV-positive individuals with CVD risk.